Aptol Pharma ApS: Financial statements 2024
CVR: 39308967
Source: annual report 2024, Danish Business Authority
01/01/2024 – 31/12/2024
Aptol Pharma ApS (CVR 39308967) has filed annual accounts for 2024. In 2024, the company reported a gross profit of DKK 2,442 and a net result of DKK -131,289 compared with DKK 307,979 the year before. That is a decrease of 99.4% compared with the year before. Equity in the 2024 report amounted to DKK -140,336. The company had 1 employee in the financial year.
- Gross Profit
- DKK 2,442
- Profit/Loss
- DKK -131,289
- Equity
- DKK -140,336
- Total Assets
- DKK 48,346
- Employees
- 1
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2024 | - | 2 t. | -131 t. | -140 t. | 1 |
| 2023 | - | 414 t. | 308 t. | -9 t. | 1 |
| 2022 | - | -422 t. | -334 t. | -317 t. | - |
| 2021 | 0 | 0 | 0 | 50 t. | - |
| 2020 | 0 | -137 t. | -2 t. | 50 t. | - |
Official annual report
Screen every Danish company
Combine filters on financials, industry, geography, property and risk, and instantly see which companies match.
Try company screeningEvents in 2024
As of February 16, 2024, Mads Hartvig Clausen has joined the board of directors of Aptol Pharma ApS.
Aptol Pharma ApS has published its annual report for 2023. Gross profit came to DKK 414,462, and the net result was DKK 307,979.
About Aptol Pharma ApS
Aptol Pharma ApS is a Danish company of the type Anpartsselskab based in København SV, founded in 2018. The company is under bankruptcy. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The company was previously named IBIO TECH ApS and Integrated biomedical technologies ApS. The company's owners include ADT HOLDING ApS, Tue Wenzel Kragstrup and Peter Andreas Nicolai Reumert Wagtmann. According to the 2024 annual report, the company had an average of 1 employee. In 2024, the company reported a gross profit of DKK 2,442 and a net result of DKK -131,289 compared with DKK 307,979 the year before. Equity in the 2024 report amounted to DKK -140,336.